Advertisement

World Journal of Urology

, Volume 36, Issue 2, pp 231–240 | Cite as

Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder

  • Mohammad Abufaraj
  • Shahrokh F. ShariatEmail author
  • Beat Foerster
  • Carmen Pozo
  • Marco Moschini
  • David D’Andrea
  • Romain Mathieu
  • Martin Susani
  • Anna K. Czech
  • Pierre I. Karakiewicz
  • Veronika Seebacher
Original Article

Abstract

Objectives

To evaluate the concordance rate of lymphovascular invasion (LVI) and variant histology (VH) of transurethral resection (TUR) with radical cystectomy (RC) specimens. Furthermore, to evaluate the value of LVI and VH at TUR for predicting non-organ confined (NOC) disease, lymph node metastasis, and survival outcomes.

Patients and methods

Two hundred and sixty-eight patients who underwent TUR and subsequent RC were reviewed. Logistic regression analyses were performed to evaluate the association of LVI and VH with NOC and lymph node metastasis at RC. Cox regression analyses were used to estimate recurrence-free survival (RFS) and cancer-specific survival (CSS).

Results

LVI and VH were detected in 13.8 and 11.2% of TUR specimens, and in 30.2 and 25.4% of RC specimens, respectively. The concordance rate between LVI and VH at TUR and subsequent RC was 69.8 and 83.6%, respectively. They were both associated with adverse pathological features such as lymph node metastasis and advanced stage. TUR LVI and VH were both independently associated with lymph node metastasis and TUR VH was independently associated with NOC. On univariable Cox regression analyses, TUR LVI was associated with RFS and CSS while TUR VH was only associated with RFS. Only TUR LVI was independently associated with RFS.

Conclusion

Detection of LVI is missed in a third of TUR specimens while VH seems more accurately identified. TUR LVI and VH are associated with more advanced disease and LVI predicts disease recurrence. Assessment and reporting of LVI and VH on TUR specimen are important for risk stratification and decision-making.

Keywords

Urothelial tumor Bladder cancer Transurethral resection Lymphovascular invasion Variant histology Prognosis Prediction Recurrence Survival 

Notes

Compliance with ethical standards

Conflict of interest

I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is advisory board member for Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Urogen and Wolff. He is speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2016) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108CrossRefPubMedGoogle Scholar
  2. 2.
    Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM et al (2016) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461.  https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMedGoogle Scholar
  3. 3.
    Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ et al (2011) Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107(6):898–904. http://www.ncbi.nlm.nih.gov/pubmed/21244604. Accessed 1 Mar 2017
  4. 4.
    Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ et al (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51(1):137–151. http://www.ncbi.nlm.nih.gov/pubmed/16793197. Accessed 5 Jan 2017
  5. 5.
    Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG et al (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12(22):6663–6676. http://www.ncbi.nlm.nih.gov/pubmed/17121885. Accessed 20 Jul 2016
  6. 6.
    Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI (2008) Nomograms for bladder cancer. Eur Urol [Internet] 54(1):41–53. http://linkinghub.elsevier.com/retrieve/pii/S0302283808000043. Accessed 3 Aug 2016
  7. 7.
    Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF (2016) The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol 13(8):471–479. http://www.nature.com/doifinder/10.1038/nrurol.2016.126. Accessed 28 Jan 2017
  8. 8.
    Quek M, Stein J, Nichols P, Cai J, Miranda G, Groshen S et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174(1):103–106. http://www.ncbi.nlm.nih.gov/pubmed/15947587. Accessed 26 Jan 2017
  9. 9.
    Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10):1402–1412. http://doi.wiley.com/10.1111/j.1464-410X.2010.09217.x. Accessed 25 Jan 2017
  10. 10.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533–6539. http://www.ncbi.nlm.nih.gov/pubmed/16116151. Accessed 26 Jan 2017
  11. 11.
    Fritsche H-M, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G et al (2010) Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an International Cohort. Eur Urol 57(2):300–309. http://linkinghub.elsevier.com/retrieve/pii/S030228380900952X. Accessed 16 Feb 2017
  12. 12.
    Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z et al (2013) Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int 111(3):404–411. http://www.ncbi.nlm.nih.gov/pubmed/22805163. Accessed 1 Mar 2017
  13. 13.
    Moschini M, Dell’ Oglio P, Luciano’ R, Gandaglia G, Soria F, Mattei A et al (2017) Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol Semin Orig Investig 35(6):335–341CrossRefGoogle Scholar
  14. 14.
    Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G et al (2014) Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology 84(5):1141–1146. http://www.ncbi.nlm.nih.gov/pubmed/25239253. Accessed 21 Feb 2017
  15. 15.
    Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L et al (2015) Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol Semin Orig Investig 33(1):18.e15–18.e20CrossRefGoogle Scholar
  16. 16.
    Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell’Oglio P et al (2016) Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience. Eur J Surg Oncol 42(5):735–743. http://linkinghub.elsevier.com/retrieve/pii/S0748798316001050. Accessed 9 Aug 2016
  17. 17.
    Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49(8):1889–1897. http://www.ncbi.nlm.nih.gov/pubmed/23466126. Accessed 21 Feb 2017
  18. 18.
    Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T et al (2007) Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 70(1):69–74. http://linkinghub.elsevier.com/retrieve/pii/S0090429507003792. Accessed 12 Jan 2017
  19. 19.
    Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G et al (2011) Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 3(2):e22. http://www.ncbi.nlm.nih.gov/pubmed/21769321. Accessed 21 Feb 2017
  20. 20.
    Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A (2016) Pathology and genetics: tumours of the urinary system and male genital system: clinical implications of the 4th Edition of the WHO classification and beyond. Eur Urol 70(1):120–123CrossRefPubMedGoogle Scholar
  21. 21.
    Mitra AP, Bartsch CC, Bartsch G, Miranda G, Skinner EC, Daneshmand S (2014) Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol Semin Orig Investig 32(2):117–127. http://www.ncbi.nlm.nih.gov/pubmed/23477878. Accessed 20 Feb 2017
  22. 22.
    Willis DL, Porten SP, Kamat AM (2013) Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 23(5):435–443CrossRefPubMedGoogle Scholar
  23. 23.
    Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y et al (2006) Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 175(6):2048–2053. http://www.ncbi.nlm.nih.gov/pubmed/16697800. Accessed 10 Apr 2017
  24. 24.
    Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4):854–855. http://www.ncbi.nlm.nih.gov/pubmed/22226583. Accessed 19 May 2016
  25. 25.
    Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O’Donnell MA et al (2009) The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 103(4):475–479. http://doi.wiley.com/10.1111/j.1464-410X.2008.08011.x. Accessed 28 Jan 2017
  26. 26.
    Gakis G, Todenhöfer T, Braun M, Fend F, Stenzl A, Perner S (2015) Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scand J Urol 49(5):382–387. http://www.ncbi.nlm.nih.gov/pubmed/25921278. Accessed 17 Feb 2017
  27. 27.
    Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ (2011) Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 107(1):46–52. http://doi.wiley.com/10.1111/j.1464-410X.2010.09635.x. Accessed 28 Jan 2017
  28. 28.
    Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180(5):1928–1932. http://www.ncbi.nlm.nih.gov/pubmed/18801529. Accessed 28 Jan 2017
  29. 29.
    Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S et al (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191(1):40–47. http://www.ncbi.nlm.nih.gov/pubmed/23911605. Accessed 20 Feb 2017
  30. 30.
    Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG (2007) Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 51(3):690–698. http://www.ncbi.nlm.nih.gov/pubmed/16904815. Accessed 16 Feb 2017

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Mohammad Abufaraj
    • 1
    • 2
  • Shahrokh F. Shariat
    • 1
    • 3
    • 4
    • 5
    Email author
  • Beat Foerster
    • 1
    • 6
  • Carmen Pozo
    • 1
    • 7
  • Marco Moschini
    • 1
    • 8
  • David D’Andrea
    • 1
  • Romain Mathieu
    • 1
    • 9
  • Martin Susani
    • 10
  • Anna K. Czech
    • 1
    • 11
  • Pierre I. Karakiewicz
    • 12
  • Veronika Seebacher
    • 13
  1. 1.Department of Urology, Comprehensive Cancer CenterMedical University of Vienna, Vienna General HospitalViennaAustria
  2. 2.Division of Urology, Department of Special SurgeryJordan University Hospital, The University of JordanAmmanJordan
  3. 3.Karl Landsteiner Institute of Urology and AndrologyViennaAustria
  4. 4.Department of UrologyUniversity of Texas Southwestern Medical CentreDallasUSA
  5. 5.Department of UrologyWeill Cornell Medical CollegeNew YorkUSA
  6. 6.Department of UrologyKantonsspital WinterthurWinterthurSwitzerland
  7. 7.Department of UrologyHospital Universitario Fundación AlcorcónMadridSpain
  8. 8.Department of Urology, Urological Research InstituteVita-Salute University, San Raffaele Scientific InstituteMilanItaly
  9. 9.Department of UrologyUniversity of RennesRennesFrance
  10. 10.Department of PathologyMedical University of ViennaViennaAustria
  11. 11.Department of UrologyJagiellonian University in KrakowKrakowPoland
  12. 12.Department of UrologyUniversity of MontrealMontrealCanada
  13. 13.Department for Gynaecology and Gynaecologic OncologyMedical University of ViennaViennaAustria

Personalised recommendations